Emerging Non-Opioid Analgesic Strategies in Total Joint Arthroplasty: Mechanisms, Evidence, and Practical Implementation.

Abstract

Total joint arthroplasty (TJA), encompassing total hip and knee arthroplasty, remains one of the most effective procedures for end-stage arthritis, but is frequently associated with substantial postoperative pain. Opioid-based analgesia, while effective, carries risks of dependence, respiratory depression, and delayed recovery. In response to the opioid crisis, multimodal non-opioid strategies have gained prominence to improve outcomes while minimizing adverse effects. This review summarized current and emerging non-opioid analgesic modalities with clinical relevance to TJA. Recent randomized controlled trials, meta-analyses, and regulatory updates were analyzed to evaluate efficacy, safety, and practical integration into perioperative care. Novel pharmacologic options-including suzetrigine (VX-548), a selective Nav1.8 sodium channel blocker; intravenous meloxicam, a parenteral COX-2 inhibitor; and extended-release liposomal bupivacaine, demonstrate meaningful opioid-sparing effects with favorable tolerability profiles. Adjunctive nonpharmacologic modalities such as transcutaneous electrical nerve stimulation (TENS), sustained-acoustic-medicine ultrasound, and acupuncture offer complementary benefits by modulating peripheral and central sensitization. Additionally, injectable hydrogel and polymer-based delivery systems represent a next generation of sustained local analgesia with the potential to extend pain control beyond 72 hours. The Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, implemented in 2025, expands Medicare reimbursement for non-opioid pain treatments, providing a key policy incentive for adoption in surgical care. Multimodal, opioid-sparing regimens that incorporate both pharmacologic and non-pharmacologic agents offer the most balanced approach to pain management after TJA. While promising, wider implementation is limited by cost, access, and a paucity of arthroplasty-specific trials. Future directions include integration of artificial intelligence to individualize regimens, use of predictive pain algorithms, and real-time physiologic pain monitoring. Broader clinical validation and economic analyses are essential to establish sustainable, patient-centered models of postoperative pain control.